Best SARMS by Use

Each SARM in production has specific functions it performs well, so SARM cycles or protocols should be tailored for specific goals and uses. An ideal SARM (selective androgen receptor modulator) is an “orally active agent with once daily dosing and anabolic effects on muscle and bone, but no or lesser activity in the prostate,” according to Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium, a seminal SARM research paper published by current president and CSO at TransMed Institute Andres Negro-Vilar.

SARMS Clinical TrialsToday there are several SARMs in various stages of testing, as well as SARMs that have been abandoned due to deleterious side-effects or lack of efficacy or biological efficiency. The promise of SARMs is that they have all or most of the beneficial (anabolic) effects of AAS (anabolic-androgen steroids), minus the harmful, androgenic, or undesired side-effects. However, each type of SARM interacts different biologically, has different experimental and medical use cases, and different ratios of anabolic to androgenic effects — with some showing noticeable virilizing effects when used at high doses.

When researching the best SARMs for your specific use case, be it experiments in weight-loss, muscle gain, bone-mineral density improvement, injury healing and prevention, or other, keep in mind that this novel class of androgen receptor ligands has yet to be approved by the FDA for retail human consumption. While current research and growing anecdotal evidence indicates SARMs could be the perfect substitute for traditional anabolic androgenic steroids (AAS), and vindicates mainstream SARM supporters, more research is needed to understand the long-term physiological effects of these compounds, especially in bodybuilding and athletics, and as a weight loss aid.

LGD-4033 (Ligandrol, VK-5211)

LGD-4033, also known as Ligandrol or VK-5211, is perhaps the most common SARM, and one of the most thoroughly researched SARMs currently available. First discovered and patented by Ligand Pharmaceuticals and currently developed by Viking Therapeutics, LGD-4033 shows a lot of potential for treatment of conditions such as muscle wasting and osteoporosis.

LGD4033 has exhibited low side effects in studies, yet it is one of the most potent anabolic SARMs. Test subjects consistently yield strong gains in muscle mass, but fat reduction is not a primary effect of this compound. Ligandrol does not aromatize to cause increases in estrogen levels. It is moderately suppressive to the body’s production natural of testosterone, however this effect is short-lived once daily dosage is stopped.

One placebo-controlled SARM study tested the effects of 0.1, 0.3, or 1.0 mg of LGD-4033 daily for 21 days on 76 healthy men between 21 and 50 years to determine how it affects blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength. The researchers concluded that LGD-4033 is safe, and is capable of increasing lean body mass without a change in the prostate-specific antigen.

Even at 1 mg, LGD-4033 leads to dose-dependent suppression of total testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, and triglyceride levels. However, hormone levels and lipids return to baseline after the discontinuation of LGD-4033 administration.

When used for its strength and muscle building effects, the average dose is around 5 mg a day, with recommended dosages at 10-20 mg a day, and maximum dose regarded to be 30 mg a day.

LGD-4033 (Ligandrol) Research Profile:

9/10
8/10
3/10
4/10

Description: A 2nd gen SARM, and best-seller. Highly anabolic. Strong effects on muscle growth and strength gains.

Known for: Bulking, fast muscle mass growth

Commonly stacked with: Typical bulking stack: LGD-4033, MK-2866, YK-11, MK-677

Side-effects: Testosterone suppression with prolonged use; few reports of other adverse side-effects

LGD-4033 (Ligandrol) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator
LGD4033, LGD-4033, Ligandrol, VK5211, Anabolicum
By mouth
none
US: Investigational New Drug
Ligand Pharmaceuticals, Viking Therapeutics

Pharmacokinetic data

24-36 hours

Identifiers

4-[(2R)-2-[(1R)-2,2,2-trifluoro-1- hydroxyethyl]pyrrolidin-1-yl]-2- (trifluoromethyl)benzonitrile
1165910-22-4
44137686
n/a
29364487
1EJT54415A

Chemical and physical data

C14H12F6N2O
338.25 g/mol
n/a
FC([C@H](O)[C@H]1CCCN1C2=CC (=C(C#N)C=C2)C(F)(F)F)(F)F
1S/C14H12F6N2O/c15-13(16,17)10-6-9(4-3-8 (10)7-21)22-5-1-2-11(22)12(23)14(18,19)20/ h3-4,6,11-12,23H,1-2,5H2/t11-,12-/m1/s1
OPSIVAKKLQRWKC-VXGBXAGGSA-N

MK-2866 (Enobosarm, Ostarine, GTx-024, S-22)

Developed for the treatment of conditions such as muscle wasting and osteoporosis by GTx Incorporated, a pharmaceutical company headquartered in Memphis, Tennessee, the use of MK-2866 by professional athletes in training sparked the 2008 ban of SARMs by WADA, the World Anti-Doping Agency. Since then, the United States Anti-Doping Agency has published a detailed profile of MK-2866, stating that the number of athletes who have tested positive for MK-2866 had increased steadily over the past few years. Because of its ubiquitous use in athletics, Ostarine is the SARM that often makes headlines.

This SARM is less potent than aforementioned LGD4033, and is commonly used in experiments involving maintaining muscle, rather than building muscle mass. Notwithstanding the much lesser anabolic effects, MK2866 has a similar profile otherwise, with side effects well-tolerated. As with Ligandrol use, no aromatisation is observed, thus recipients are not prone to estrogen-related side effects such as Gynecomastia (“gyno”).

MK-2866 has been shown to increase the rate of collagen synthesis and (re)build tendons, thus its use in injury prevention and repair is ideal. Interestingly, significant increases in bone density are also universally observed in recipients, making Ostarine a powerful weapon in the fight against osteoporosis.

To determine the effects of MK-2866 on muscle wasting and physical function, researchers enrolled male and female patients with cancer who had at least 2 percent weight loss in the previous 6 months. Patients received once-daily oral MK-2866 1 mg, 3 mg, or placebo for up to 113 days, and change in total lean body mass from baseline was measured at the end of the study. “Compared with baseline, significant increases in total lean body mass by day 113 or end of the study were noted in both MK-2866 groups,” the researchers concluded. No serious side-effects were recorded.

Athletes who use MK-2866 for its performance-enhancing benefits use doses of up to 20-30 mg a day, while smaller doses (eg. 15 mg daily) is common when stacking SARMS. Such high doses often lead to a modest degree of suppression of the hypothalamic–pituitary–gonadal axis (HPG axis), which controls how much testosterone the testes produce and secrete. As such, a short PCT (post cycle therapy) is generally used to restore natural testosterone production.

MK-2866 (Ostarine) Research Profile:

6/10
6/10
5/10
5/10

Description: 1st gen SARM, very common, very versatile. Moderate, consistent effects on muscle and strength gains. "Injury assist" SARM with positive effects on bone, ligaments, tendons.

Known for: Versatility (synergizes any stack), injury recovery

Commonly stacked with: Synergistic effects with any other SARM or stack

Side-effects: Very few reports of adverse side-effects

MK-2866 (Ostarine) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator
Enobosarm, Ostarine, GTx-024, MK-2866, S-22
By mouth
none
US: Investigational New Drug
GTx, Merck & Co.

Pharmacokinetic data

24 hours

Identifiers

((2S)-3-(4-cyanophenoxy)-N- [4-cyano-3-(trifluoromethyl)phenyl] -2-hydroxy-2-methylpropanamide)
841205-47-8
11326715
9501667
O3571H3R8N
D10221

Chemical and physical data

C19H14F3N3O3
389.33 g/mol
132 to 136 °C (270 to 277 °F)
O=C(NC1=CC=C(C#N)C(C(F)(F)F)=C1) [C@](C)(O)COC2=CC=C(C#N)C=C2
1S/C19H14F3N3O3/ c1-18(27,11-28-15-6-2-12(9-23) 3-7-15)17(26)25-14-5-4-13(10-24) 16(8-14)19(20,21)22/h2-8, 27H,11H2,1H3,(H,25,26)/t18-/m0/s1
JNGVJMBLXIUVRD-SFHVURJKSA-N

RAD-140 (Testolone)

LGD4033 CapsulesThe newest popular SARM and the most powerful in terms of anabolic activity, RAD140 has recently made waves in the medical community because its developer, Radius Health, announced that the first patient had been enrolled in the company’s Phase 1 study of the SARM.

Along with the promising potential use of RAD140 in hormone receptor-positive breast cancer, this SARM is perhaps known best for muscle-mass-enhancement, due to its very high ratio of anabolic to androgenic effects, which are estimated at 90:1, the highest ratio of all SARMs. No wonder then that the muscle-building effects of RAD140 rival even some AAS, but without the high androgenic side effects associated with the use of traditional steroids. When used for building muscle, doses typically range from 4 mg a day to 12 mg a day, and most RAD140 experiments end in 6 weeks, followed by 3 weeks of mild PCT.

RAD-140 (Testalone) Research Profile:

10/10
8/10
2/10
3/10

Description: A 3rd gen SARM. Extremely anabolic. Purported to have strongest effects on muscle growth and strength gains.

Known for: Bulking, fast muscle mass growth

Commonly stacked with: Typical bulking stack: RAD-140, MK-2866, YK-11, MK-677

Side-effects: Testosterone suppression with prolonged use; few reports of other adverse side-effects

RAD-140 (Testalone) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator
Testalone, Testolone, RAD-140
By mouth
none
US: Investigational New Drug
Radius Health, Inc.

Pharmacokinetic data

12-18 hours

Identifiers

2-chloro-4-{[(1R,2S)-1-[5-(4-cyanophenyl) -1,3,4-oxadiazol-2-yl]-2-hydroxypropyl] amino}-3-methylbenzonitrile
1182367-47-0
44200882
26387625
4O87Q44KNC
none

Chemical and physical data

C20H16ClN5O2
389.33 g/mol
n/a
ClC1=C(C#N)C=CC(=C1C)N[C@H]([C@H] (C)O)C2=NN=C(O2)C3=CC=C(C=C3)C#N
1S/C20H16ClN5O2/c1-11-16(8-7-15 (10-23)17(11)21)24-18(12(2)27) 20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/ h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
Key:XMBUPPIEVAFYHO-KPZWWZAWSA-N

YK-11

Even though YK-11 is typically considered a SARM, it is actually a gene-selective partial agonist of the androgen receptor, sometimes referred to as a synthetic steroid, with a molecular structure not shared with other SARMs.  YK11 is myostatin inhibitor (myostatin regulates muscle growth limits) and is a testosterone/5-α-dihydrotestosterone (DHT) derivative. It has the same chemical backbone (characterized by three fused cyclohexane rings and a single cyclopentane ring) as other chemicals classified as steroid hormones.

Most information we have about YK-11 comes from two papers published by Kanno Y et al. 2011 and 2013. Both of these papers show YK-11 has anabolic activity in vitro and potentially greater potency with considerably fewer side-effects than traditional steroids. Importantly, these data originate from studies on mice cells outside their normal biological context, thus care must be given when translating its use context to human beings. It is expected, however, that YK-11 contributes to muscle mass increase, hardness and strength.

Anecdotal experience of people using this compound for muscle-building and strength-training purposes confirms its positive effects on strength, but more research is needed to determine the optimal dose.

YK-11 (Myostatin Inhibitor) Research Profile:

dependent on stack
dependent on stack
dependent on stack
dependent on stack

Description: Myostatin inhibitor -- reduces muscle-growth limitations imposed by naturally-occurring myostatin protein.

Known for: Inhibiting effects of Myostatin

Commonly stacked with: Typical bulking stack: YK-11, MK-677, MK-2866, and RAD-140/or/LGD-4033/or/S-4

Side-effects: Very few reports of adverse side-effects

YK-11 (Myostatin Inhibitor) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator, Myostatin Inhibitor
YK-11, YK11, (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester
By mouth
none
US: Investigational New Drug
Excenen Pharmatech, ChemIDplus

Pharmacokinetic data

6-10 hours

Identifiers

Methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2'-methoxy-2', 13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15, 16-dodecahydrocyclopenta[a]phenanthrene -17,5'-1,3-dioxolane]-4'-ylidene]acetate
1370003-76-1
119058028
52085570
Z9748J6B0R

Chemical and physical data

C25H34O6
430.54 g/mol
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\ C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35
1S/C25H34O6/c1-23-11-9-18-17-8-6-16(26) 13-15(17)5-7-19(18)20(23)10-12-25(23)21(14-22(27) 28-3)30-24(2,29-4)31-25/h13-14,17-20H,5-12H2,1- 4H3/b21-14+/t17-,18+,19+,20-,23-,24?,25+/m0/s1
KCQHQCDHFVGNMK-PQUNLUOYSA-N

S-4 (Andarine)

Commonly known as Andarine, S-4 is developed by GTx Incorporated for the treatment of conditions such as muscle wasting, osteoporosis, and benign prostatic hypertrophy. While less potent than other SARMs, with lower anabolic and androgenic effects, relatively low doses of S-4 have been found to build muscle mass in rodents, demonstrating tissue-selective pharmacological activity.

A recent study has studied the metabolite of S-4 in plasma by administering the compound to in equine testing. The study found administration of S-4 leads to three major metabolic reactions: amide hydrolysis, hydroxylation, and sulfonation, and products of these metabolic reactions could be detected for 12 hours. These insights help researchers determine appropriate targets for doping control as S-4 becomes increasingly popular as a performance-enhancing drug because of its ability to increase muscle and bone mass without affecting the prostate.

S-4 is often taken in doses of up to 50 mg a day for 4 to 8 weeks. Doses exceeding 50 mg have been anecdotally confirmed to cause temporary vision problems, such as a yellow tint in vision. These side-effects are known to subside soon after discontinuation of usage.

S-4 (Andarine) Research Profile:

7/10
6/10
5/10
4/10

Description: A 1st gen SARM. Very anabolic. Moderate metabolic improvements. Tried-and-true.

Known for: Bulking, muscle mass, some fat loss

Commonly stacked with: Typical bulking stack: S-4, MK-2866, YK-11, MK-677

Side-effects: Testosterone suppression with prolonged use; temporary blurry or "yellow tint" vision in some users

S-4 (Andarine) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator
S4, S-4, Andarine, Andarin, Acetamidoxolutamide, Androxolutamide, GTx-007
By mouth
none
US: Investigational New Drug
GTX, Inc.

Pharmacokinetic data

4-6 hours

Identifiers

(2S)-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl-N- (4-nitro-3-trifluoromethyl-phenyl)-propionamide
401900-40-1
9824562
7849
DB07423
8000309
125236
100.230.653

Chemical and physical data

C19H18F3N3O6
441.357 g/mol
n/a
FC(F)(F)c1cc(ccc1[N+]([O-])=O)NC (=O)[C@@](O)(COc2ccc(cc2)NC(=O)C)C
1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14 (7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30) 15(9-13)19(20,21)22/h3-9,28H,10H2, 1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
YVXVTLGIDOACBJ-SFHVURJKSA-N

MK-677 (Ibutamoren)

MK677 is produced by Reverse Pharmacology, which markets the drug as Nutrobal, designed to stimulate the pituitary gland to release growth hormone. MK677 is an orally-active growth hormone secretagogue, thus it mimics human growth hormone (HGH)-stimulating action of the hormone ghrelin (source). This SARM behaves like oral-HGH, stimulating GH/insulin-like growth factor-I. It has a longer-than-usual half life of 24 hours, and is often administered in long-term experiments.

Ibutamoren was originally designed to mitigate obesity, muscle wasting, and osteoporosis (source). In testing, Ibutamoren boosts IGF-1 serum concentration and plasma growth hormone (GH) levels in both humans and animals, and stimulates body weight changes such as increases in lean body mass. Side-effects include increase in hunger and, potentially, increases in cortisol levels. Increased insulin resistance is noted within 6 weeks, with significant body fat decreases after 26 weeks.

Like MK-2866, the MK-677 SARM is often used within athletics and bodybuilding as a performance-enhancer, despite warnings from the FDA and WADA. Typical study dosing is observed at 10mg-15mg daily. Ancillary benefits often attributed to MK677 include healing of ligaments, tendons, bones, and injuries, gains in size and lean muscle mass, improvments in skin tone and elasticity, and increases in oxidation and higher utilization of fat stores.

MK-677 (Ibutamoren) Research Profile:

dependent on stack
dependent on stack
7/10 (cutting stack)
dependent on stack

Description: Growth Hormone (GH) mimetic/secretegogue; effects include improved lean muscle generation, improved metabolism and fat oxidization; some subjects also exhibit healthier skin and sleep improvement.

Known for: Mimicking effects of Growth Hormone

Commonly stacked with: Typical bulking stack: MK-677, MK-2866, YK-11 and RAD-140/or/LGD-4033/or/S-4
Typical cutting stack: MK-677, MK-2866, and GW-501516 or SR-9009

Side-effects: Some complain of lethargy, increased appetite, tingly or numb hands/fingers

MK-677 (Ibutamoren) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator MK-677, MK-0677, Ibutamoren, L-163,191, Nutrobal, Oratrope By mouth none US: Investigational New Drug Ammonett Pharma

Pharmacokinetic data

24 hours

Identifiers

2-amino-2-methyl-N-[1-(1-methylsulfonylspiro [2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3 -phenylmethoxypropan-2-yl]propanamide 159634-47-6 9939050 n/a 154975 GJ0EGN38UL n/a 100.236.734

Chemical and physical data

C27H36N4O5S 528.662 g/mol n/a O=S(C)(=O)N(C2)c1ccccc1C23CCN(CC3) C(=O)C(NC(=O)C(N)(C)C)COCc4ccccc4 1S/C27H36N4O5S/c1-26(2,28)25(33)29-22 (18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27 (14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/ h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1 UMUPQWIGCOZEOY-JOCHJYFZSA-N

GW-501516 (Cardarine)

Cardarine and Stenabolic for increased athletic enduranceGW-501516 has been linked in studies to dramatic improvements in metabolism, endurance and general physical performance. Maker GSK completed two phase II clinical studies relating to reduction in obesity, diabetes and cardiovascular disease, but discontinued development of Cardarine when animal testing revealed its propensity for carcinogenic risk.

Health benefits purported by Cardarine researchers include improved immune system support, brain and heart health & protection, and mild muscle growth. Cardarine, however, is most often associated with increases in metabolism, stamina and endurance, qualities sought after by runners and cyclists, since its binds to and activates PPAR delta (peroxisome proliferator activator receptors), and AMPK and PPAδ agonists are exercise mimetics (source).

Reported dosages range from 5-10mg daily.

GW-501516 (Cardarine) Research Profile:

3/10
4/10
8/10
9/10

Description: A 1st gen SARM. Known as the "endurance SARM". Excellent for fat loss. Slight anabolic activity. Similar to SR-9009 but longer half-life so use as all-day fat burn.

Known for: Endurance activities, weight loss, cutting

Commonly stacked with: Typical cutting stack: GW-501516, MK-2866, MK-677

Side-effects: Very few reported; one study in rats showed ultra-high doses could cause cancer

GW-501516 (Cardarine) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator
GW501516, GW-501516, Cardarine, Endurobol, GSK-516
By mouth
none
US: Unscheduled
GSK, Ligand Pharmaceuticals

Pharmacokinetic data

20-24 hours

Identifiers

{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl] -1,3-thiazol-5-yl}methyl) sulfanyl]-2-methylphenoxy}acetic acid
317318-70-0
9803963
2687
7979723
7I2HA1NU22
n/a
73726
ChEMBL38943

Chemical and physical data

C21H18F3NO3S2
453.498 g/mol
n/a
O=C(COc1ccc(SCc2c(C)nc (c3ccc(C(F)(F)F)cc3)s2)cc1C)O
InChI=1S/C21H18F3NO3S2/ c1-12-9-16 (7-8-17(12)28-10-19(26)27)29-11-18-13 (2)25-20(30-18)14-3-5-15(6-4-14)21 (22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
YDBLKRPLXZNVNB-UHFFFAOYSA-N

SR-9009 (Stenabolic)

While not technically a SARM, Stenabolic is often classified as such due to it’s clinical outcomes, including enhanced muscle growth and fat oxidization. SR-9009 was first developed in 2013 by Scripps Research (hence ‘SR’) Institute as an agonist (enhancer) of Rev-ErbA, the proteins that stabilize the internal clock in mammals.

Although SR-9009 was created to study and assist our circadium (sleep) rhythm, other study outcomes included reduction in anxiety, and increases in muscle growth and endurance. Mechanisms responsible for this increased exercise capacity are increased oxygen consumption and increased mitochondria counts in skeletal muscle.

Further benefits included decreases cholesterol, weight, and inflammation in studies in mice, as the REV-ERB proteins decrease triglyceride production and turn off genes responsible for fat storage.

SR-9009 (Stenabolic) Research Profile:

4/10
5/10
8/10
9/10

Description: A 3rd gen SARM. The weight-loss and endurance properties of Cardarine/GW-501516, but mild anabolic and shorter half-life so use if targeting training/workout sessions.

Known for: Endurance, stamina, weight loss

Commonly stacked with: Typical cutting stack: SR-9009, MK-2866, MK-677

Side-effects: Very few anecdotal reports of adverse side-effects

SR-9009 (Stenabolic) Chemical Profile:

Clinical data

Selective Androgen Receptor Modulator SR9009, SR-9009, Stenabolic By mouth none US: Investigational New Drug Scripps Research Institute

Pharmacokinetic data

4-6 hours

Identifiers

ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl) methyl)amino)methyl)pyrrolidine-1-carboxylate 1379686-30-2 57394020 28487410 1961796

Chemical and physical data

C20H24ClN3O4S 437.94026 g/mol CCOC(=O)N1CCC(C1)CN(CC2=CC=C (C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-] 1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16 (13-23)12-22(11-15-3-5-17 (21)6-4-15)14-18-7-8-19 (29-18)24 (26)27/h3-8,16H,2,9-14H2,1H3 MMJJNHOIVCGAAP-UHFFFAOYSA-N

 


* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Selective Androgen Receptor Modulators (SARMs) have not been approved in the US by the FDA for human consumption as dietary supplements. In accordance with US laws pertaining to the use of Investigtional New Drugs (IND’s) products labeled as SARMs on sarmtech.net are sold for laboratory and clinical research purposes only, are intended solely for investigational use, and are to be used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application; otherwise, you are not authorized to purchase our SARM products. By using this site and/or purchasing our products, you agree SARMTECH is not liable for any unintended effects or outcomes. You are not permitted to sell or resell any of our products. You are not permitted to use or purchase from sarmtech.net if you are under 21 years of age.